Glycoprotein IIb/IIIa Antagonists Induce Apoptosis in Rat Cardiomyocytes by Caspase-3 Activation*

  1. Sharon R. Adderley and
  2. Desmond J. Fitzgerald
  1. From the Centre for Cardiovascular Science, Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin 2, Ireland

    Abstract

    The platelet integrin glycoprotein (GP) IIb/IIIa, which mediates platelet aggregation, has been the target for novel antiplatelet agents, the GPIIb/IIIa antagonists. Several GPIIb/IIIa antagonists have been developed based on the peptide RGDS present in adhesion proteins, including the principle ligand fibrinogen. The apoptosis enzyme, procaspase-3, contains an RGD-recognition sequence and is activated by RGDS. We examined the effects of RGDS and several GPIIb/IIIa antagonists on cell death and procaspase-3 activation in rat neonatal cardiomyocytes. These antagonists do not recognize rat integrins, yet RGDS, orbofiban, and xemilofiban induced dose-dependent apoptosis and procaspase-3 activation in cardiomyocytes over 72 h, particularly under hypoxic conditions. Scrambled peptide, the monoclonal antibody 7E3 or integrelin (a peptide containing a KGD sequence), had little or no effect. Immunoprecipitation of procaspase-3 followed by treatment with the compounds showed that procaspase-3 was activated directly by RGDS, orbofiban, xemilofiban, and by monoclonal 7E3 antibody, the latter demonstrating that compounds must enter cells to induce apoptosis through caspase activation. Integrelin had no effect. Binding studies with 3H-SC52012B, a GPIIb/IIIa antagonist analogue of orbofiban, showed no specific binding to cardiomyocytes, but the radioligand accumulated intracellularly over 72 h.3H-SC52012B also bound directly to human recombinant caspase-3 (K d, 59 ± 2 nm), and this was prevented by orbofiban, xemilofiban, and the monoclonal 7E3 antibody but not by integrelin. Finally confocal microscopy showed that RGDS co-localized with caspase-3 inside the cell. These data show that RGDS and its mimetics induce cardiomyocyte apoptosis by direct activation of procaspase-3.

    Footnotes

    • * This work was supported by the Health Research Board of Ireland, the Higher Education Authority of Ireland, the Irish Heart Foundation, and the Royal College of Surgeons in Ireland.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • To whom correspondence and reprints requests should be addressed: Centre for Cardiovascular Science, Royal College of Surgeons in Ireland, 123, St. Stephens Green, Dublin 2, Ireland. Tel.: 353-1-4782165; Fax: 353-1-4022453; E-mail: dfitzgerald@rcsi.ie.

    • Abbreviations:
      GPIIb/IIIa

      glycoprotein IIb/IIIa

      PBS

      phosphate-buffered saline

      HBSS

      Hank's balanced salt solution

      mAb

      monoclonal antibody

      ELISA

      enzyme-linked immunosorbent assay

      HUVEC

      human umbilical vein endothelial cells

      pNA

      p-nitroaniline

      • Received September 7, 1999.
      • Revision received November 15, 1999.
    « Previous | Next Article »Table of Contents
    • Advertisement
    • Advertisement
    Advertisement